• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

聚乙二醇干扰素联合利巴韦林在韩国慢性丙型肝炎的再治疗中应用。

Pegylated interferon and ribavirin in the retreatment of chronic hepatitis C in Korea.

机构信息

Division of Gastroenterology, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.

出版信息

Gut Liver. 2013 Sep;7(5):585-93. doi: 10.5009/gnl.2013.7.5.585. Epub 2013 Aug 14.

DOI:10.5009/gnl.2013.7.5.585
PMID:24073317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3782674/
Abstract

BACKGROUND/AIMS: Pegylated interferon (peginterferon) and ribavirin is the current standard therapy for chronic hepatitis C. The aims of this study were to evaluate the efficacy of peginterferon and ribavirin and to identify predictors of a sustained virological response (SVR) to the retreatment of chronic hepatitis C in Korea.

METHODS

The clinical records of 91 patients with chronic hepatitis C who were retreated with peginterferon and ribavirin were retrospectively analyzed. None of the patients had previously attained a SVR, and the patients were categorized according to their previous responses (nonresponder, relapser, or inadequate treatment) to conventional interferon/ribavirin.

RESULTS

The overall SVR rate was 54.9%. Independent predictors of a SVR were genotypes 2 and 3, relapse, an adherence to peginterferon of over 80%, and an early virological response (EVR). For genotype 1 patients, an adherence to peginterferon of over 80% was an independent predictor of a SVR.

CONCLUSIONS

Peginterferon and ribavirin therapy is effective for the retreatment of Korean chronic hepatitis C patients who have failed interferon/ribavirin, especially in patients with genotypes 2 and 3, relapse, an adherence to peginterferon over 80%, and an EVR. For genotype 1 patients, retreatment was effective in patients with an adherence to peginterferon over 80%.

摘要

背景/目的：聚乙二醇干扰素（peginterferon）和利巴韦林是慢性丙型肝炎的当前标准治疗方法。本研究的目的是评估 peginterferon 和利巴韦林的疗效，并确定韩国慢性丙型肝炎再治疗中持续病毒学应答（SVR）的预测因素。

方法

回顾性分析了 91 例接受 peginterferon 和利巴韦林再治疗的慢性丙型肝炎患者的临床记录。这些患者均未达到 SVR，且根据他们对常规干扰素/利巴韦林的既往反应（无应答者、复发者或治疗不足者）进行分类。

结果

总的 SVR 率为 54.9%。SVR 的独立预测因素包括基因型 2 和 3、复发、peginterferon 的依从性超过 80%以及早期病毒学应答（EVR）。对于基因型 1 患者，peginterferon 的依从性超过 80%是 SVR 的独立预测因素。

结论

聚乙二醇干扰素和利巴韦林治疗对干扰素/利巴韦林治疗失败的韩国慢性丙型肝炎患者再治疗有效，特别是在基因型 2 和 3、复发、peginterferon 的依从性超过 80%以及 EVR 的患者中。对于基因型 1 患者，peginterferon 的依从性超过 80%的患者再治疗有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6061/3782674/7c127d059467/gnl-7-585-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6061/3782674/d2d455790337/gnl-7-585-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6061/3782674/7c127d059467/gnl-7-585-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6061/3782674/d2d455790337/gnl-7-585-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6061/3782674/7c127d059467/gnl-7-585-g002.jpg

相似文献

1
Pegylated interferon and ribavirin in the retreatment of chronic hepatitis C in Korea.聚乙二醇干扰素联合利巴韦林在韩国慢性丙型肝炎的再治疗中应用。
Gut Liver. 2013 Sep;7(5):585-93. doi: 10.5009/gnl.2013.7.5.585. Epub 2013 Aug 14.
2
Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.聚乙二醇干扰素α-2a（40KD）（派罗欣）联合利巴韦林（Copegus）用于既往接受过传统干扰素联合利巴韦林治疗无应答和复发的慢性丙型肝炎患者的再治疗。
Braz J Infect Dis. 2006 Feb;10(1):11-6. doi: 10.1590/s1413-86702006000100003. Epub 2006 Jun 2.
3
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.预测对聚乙二醇干扰素 α-2b 联合利巴韦林无应答的既往无应答者经聚乙二醇干扰素 α-2a 联合利巴韦林再治疗的早期和持续病毒学应答以及再治疗的获益-风险比。
J Clin Gastroenterol. 2013 Oct;47(9):786-93. doi: 10.1097/MCG.0b013e31827b9b45.
4
Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.聚乙二醇干扰素 α-2a+利巴韦林治疗对既往聚乙二醇干扰素 α-2b+利巴韦林联合治疗应答不佳患者的疗效。
Dig Dis. 2012;30(6):554-60. doi: 10.1159/000343064. Epub 2012 Dec 13.
5
Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.对复发或对首个聚乙二醇化干扰素治疗疗程无反应的慢性丙型肝炎患者，采用聚乙二醇化干扰素α-2a和利巴韦林进行再治疗。
Can J Gastroenterol. 2009 Mar;23(3):180-4. doi: 10.1155/2009/470532.
6
[Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].聚乙二醇化干扰素和利巴韦林对韩国慢性丙型肝炎病毒感染患者的疗效
Korean J Hepatol. 2008 Sep;14(3):318-30. doi: 10.3350/kjhep.2008.14.3.318.
7
Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.聚乙二醇干扰素α-2a联合利巴韦林与聚乙二醇干扰素α-2a单药治疗初治慢性丙型肝炎患者早期病毒学应答者的疗效比较，以及聚乙二醇干扰素α-2a联合利巴韦林与聚乙二醇干扰素α-2a、利巴韦林及金刚烷胺三联疗法治疗早期病毒学无应答者的疗效比较：SMIEC II试验
Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.
8
[Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].[慢性丙型肝炎持续病毒学应答的持久性：聚乙二醇干扰素联合利巴韦林治疗实现持续病毒学应答后复发相关因素分析]
Korean J Gastroenterol. 2011 Mar;57(3):173-9. doi: 10.4166/2011.57.3.173.
9
High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.早期病毒动力学对标准联合治疗无应答的慢性丙型肝炎患者再次使用聚乙二醇干扰素和利巴韦林治疗具有较高预测价值。
J Hepatol. 2007 Apr;46(4):596-604. doi: 10.1016/j.jhep.2006.10.016. Epub 2006 Nov 27.
10
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.聚乙二醇干扰素 α 和利巴韦林治疗适合缩短疗程、再治疗或合并 HCV/HIV 感染的慢性丙型肝炎患者：系统评价和经济评估。
Health Technol Assess. 2011 Apr;15(17):i-xii, 1-210. doi: 10.3310/hta15170.

本文引用的文献

1
Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.聚乙二醇干扰素 α-2a（40kD）联合利巴韦林治疗慢性丙型肝炎患者的疗效和安全性：在中欧和东欧进行的一项开放性研究，这些患者先前对干扰素和利巴韦林的治疗失败。
Eur J Gastroenterol Hepatol. 2011 May;23(5):375-81. doi: 10.1097/MEG.0b013e3283458407.
2
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients.白细胞介素 28B 基因附近单核苷酸多态性与亚洲患者对丙型肝炎治疗的反应相关。
J Gastroenterol Hepatol. 2011 Sep;26(9):1374-9. doi: 10.1111/j.1440-1746.2011.06744.x.
3
Boceprevir for previously treated chronic HCV genotype 1 infection.博赛泼维用于治疗既往慢性 HCV 基因 1 型感染。
N Engl J Med. 2011 Mar 31;364(13):1207-17. doi: 10.1056/NEJMoa1009482.
4
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.欧洲肝脏研究学会临床实践指南：丙型肝炎病毒感染的管理
J Hepatol. 2011 Aug;55(2):245-64. doi: 10.1016/j.jhep.2011.02.023. Epub 2011 Mar 1.
5
Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment.目前对干扰素α为基础治疗失败的慢性丙型肝炎患者的抗病毒联合治疗。
J Clin Pharm Ther. 2011 Dec;36(6):695-703. doi: 10.1111/j.1365-2710.2010.01231.x. Epub 2010 Dec 22.
6
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?聚乙二醇干扰素联合利巴韦林治疗干扰素联合利巴韦林无应答的丙型肝炎患者。在现实生活中是否有所不同？
BMC Infect Dis. 2010 Jul 20;10:212. doi: 10.1186/1471-2334-10-212.
7
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.肝组织干扰素刺激基因表达与白细胞介素 28B 基因多态性及慢性丙型肝炎干扰素治疗结局相关。
Gastroenterology. 2010 Aug;139(2):499-509. doi: 10.1053/j.gastro.2010.04.049. Epub 2010 Apr 29.
8
Telaprevir for previously treated chronic HCV infection.替拉瑞韦治疗既往治疗的慢性 HCV 感染。
N Engl J Med. 2010 Apr 8;362(14):1292-303. doi: 10.1056/NEJMoa0908014.
9
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.IL28B全基因组与聚乙二醇化干扰素-α和利巴韦林治疗慢性丙型肝炎疗效的关联研究
Nat Genet. 2009 Oct;41(10):1105-9. doi: 10.1038/ng.449. Epub 2009 Sep 13.
10
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.白细胞介素28B的基因变异可预测丙型肝炎治疗诱导的病毒清除情况。
Nature. 2009 Sep 17;461(7262):399-401. doi: 10.1038/nature08309. Epub 2009 Aug 16.